Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDR001 plus platinum-doublet chemotherapy in metastatic NSCLC
NL-OMON45593Phase 1Completed
- Sponsor
- Novartis
- Start
- Apr 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of spartalizumab in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Novartis. Primary endpoints: Dose Limiting Toxicities and Overall response rate. Started Apr 2018; status: completed.
02
Drugs
spartalizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON45593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45593.